Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

HR 2718/S 1110 - MedPAC Reform Act of 2009
HR 2307/S 1004 - Reaching Elders with Assessment and Chronic Care Management and Coordination Act
S 1634 - The Medicare Prescription Drug Improvement Act of 2009
Under Line 17: We would like to include the Office of the National Coordinator for Health Information Technology
S 266 - Medicare Prescription Drug Gap Reduction Act of 2009
HR 203 - Medicare Fraud Prevention Act of 2009
HR 27 - Medicare Fraud Prevention and Enforcement Act of 2009
HR 616/S 511 - Access to Durable Medical Equipment Act
HR 574/S 254 - Medicare Home Infusion Therapy Coverage Act of 2009
HR 2560/S 1131 - Independence At Home Act
HR 1970/S 956 - Preserve Patient Access to the Reputable DMEPOS Providers Act of 2009
HR 3700/S 1951 - Fair Medicaid Drug Payment Act (From 110th Congress)/Concept to Include Medicaid Average Manufacturers Price Reimbursement Formula in Health Care Reform
HR 3108 - Medication Therapy Managament Benefits Act of 2009/Concept to Include Medication Therapy Management Provisions in Health Care Reform
HR 3663 - Amends the Social Security Act to delay the October 1, 2009 deadline on which the accreditation requirement under the Medicare Program applies to suppliers of durable medical equipment that are pharmacies. (Public Law 111-72)
S 683 - Community Choice Act of 2009
HR 1392/S 1221 - Amends the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price

(Public Law 110-275) Medicare Improvements for Patients and Providers Act of 2008 sections on Medicare DMEPOS

(Docket Number CMS-4085-P) Medicare Program; Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs
(Docket Number: CMS1561IFC) Medicare Program; Changes to the Competitive Acquisition of Certain Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) by Certain Provisions of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA)
(Docket Number: CMS-1540-F) Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2007; Certain Provisions Concerning Competitive Acquisition for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS); Accreditation of DMEPOS Suppliers
(Docket Number: CMS-6006-F) Medicare Program: Surety Bond Requirement for Suppliers of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)
(Docket No. CMS-4085-P) Medicare Program; Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs
Docket Number: CMS-10260 (OMB#: 0938-1051) Collection Activities; Medicare Advantage and Prescription Drug Program: Final Marketing Provisions

(74 FR 28937) ONC Draft Recommendations for the Term "Meaningful Use" of Electronic Health Records

CMS August 2009 Memo: Fraud, Waste and Abuse (FWA) Training Clarification (regarding changes to 42 C.F.R. 422.503(b)(4)(vi) and 42 C.F.R. 423.504 (b)(4)(vi))

Final 2010 Medicare Part D Call Letter
Draft Part D Model Notices for Beneficiaries: Mail-Order and Excluded Provider

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

S 754 - The Methadone Treatment and Protection Act of 2009
HR 2855 - The Drug Overdose Reduction Act
S 256 - Combat Methamphetamine Enhancement Act of 2009
HR 1706 - Protecting Consumer Access to Generic Drugs Act of 2009
HR 3018 - Amend the Controlled Substance Act to address the use of intrathecal pumps
HR 1204 - The Community Pharmacy Fairness Act of 2009
S 80 - Pharmaceutical Market Access Act of 2009
HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009
HR 163 - Prescription Drug Affordability Act

(Docket Number FDA2009D0461) FDA Draft Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications
(Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting on the types of communications that patients receive at the pharmacy including: medication guides; patients package inserts; and consumer medication information
(Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all pharmacy-based communications
(Docket Number FDA2009D0181) Draft Guidance for Industry on Label Comprehension Studies for Nonprescription Drug Products; Availability
(Docket Number FDA2009N0295) Providing Effective Information to Consumers About Prescription Drug Risks and Benefits; Public Workshop
(Docket Number FDA1977N0013) (formerly Docket No. 1977N0094L) Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph
(Docket Number FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting
(Docket Number FDA2006N0238) (formerly Docket No. 2006N0062) Expanded Access to Investigational Drugs for Treatment Use
(Docket Number FDA2006N0237) (formerly Docket No. 2006N0061) Charging for Investigational Drugs Under an Investigational New Drug Application
(Docket Number FDA2009N0247) Food and Drug Administration Transparency Task Force; Reopening of Comment Period
(Docket Number DEA321) Identification of Institution-based Individual Practitioners
(Docket Number FDA2009N0374) Educating the Public About Removal of Essential-Use Designation for Epinephrine; Public Workshop; Request for Comments
(Docket Number FDA2009N0441) Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing
(Docket Number FDA-2009-N-0138) Liver Injury Related to the Use of Acetaminophen; Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee and the Anesthetic and Life Support Drugs Advisory Committee
(DEA Information Collection 1117-0046) Self-Certification, Training and Logbooks for Regulated Sellers of Scheduled Listed Chemical Products
(Docket Number FDA2008N0424) Postmarketing Safety Reporting for Combination Products
(Docket Number FDA2009N0664) Risk Communication Advisory Committee; Notice of Meeting

Concept - Medication Adherence
Concept - Pharmacogenomics
Concept - Oppose Liberalizing Prescription Drug Importation
Concept - Agent of the Prescriber

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

S 750 - Caring for an Aging America Act
HR 2891 - Access to Frontline Health Care Act of 2009
HR 756/S 660 - National Pain Care Policy Act of 2009
Under Line 17: We would like to include the Agency for Healthcare Research and Quality (AHRQ)
HR 1259 - Dextromethorphan Distribution Act of 2009
HR 1256 - Family Smoking Prevention and Tobacco Control Act on smoking cessation, advertising and marketing of tobacco products; and sale and distribution of tobacco.
S 1213 - A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research.
HR 2345 - Amends the Fair Credit Reporting Act to provide for an exclusion from Red Flag Guidelines for health care practices
S 1213 - Patient-Centered Outcomes Research Act of 2009

S 1679 Affordable Health Choices Act [Sections on: ensuring quality of care; affordable choices of health benefit plans; seeking the best medical advice; spending for Federally Qualified Health Centers; national strategy; presentation of drug information; center for health outcomes research and evaluation; administrative simplification; right choices program; grants to establish community health teams to support a medical home model; grants to implement medication therapy management services in treatment of chronic disease; national health care workforce commission; funding for National Health Service Corps; geriatric education and training, career awards, comprehensive geriatric education; nurse education, practice, and retention grants; increasing Access to clinical preventive services, and increase prevention and wellness provisions.]

HR 3200 - America's Affordable Health Choices Act of 2009 [Sections on: ensuring adequacy of provider networks; essential benefits package defined; Health Benefits Advisory Committee; outreach and enrollment of exchange-eligible individuals and employers in Exchange-participating health benefits plan; payment rates for items and services; reducing potentially preventable hospital readmissions; post acute care services payment reform plan; requiring drug manufacturers to provide drug rebates for certain, full premium subsidy eligible individuals; phasedin elimination of coverage gap; repeal of provision relating to submission of claims by pharmacies located in or contracting with long-term care facilities; including costs incurred by AIDS drug assistance programs and Indian Health Service in providing prescription drugs toward the annual out of pocket threshold under part D; permitting mid-year changes in enrollment; telehealth expansion and enhancements; intelligent assignment in enrollment; ensuring effective communication in Medicare; Accountable Care Organization pilot program; medical home pilot program; coverage and waiver of cost-sharing for preventive services; comparative effectiveness research; reports on financial relationships between manufacturers and distributors of covered drugs, devices, biologicals, or medical supplies under Medicare, Medicaid, or CHIP and physicians and other health care entities and between physicians and other health care entities; distribution of unused residency positions; require providers and suppliers to adopt programs to reduce waste, fraud, and abuse; payments to pharmacists (AMP); Task Force on Clinical Preventive Services; fully integrated dual eligible special needs plans; public health and workforce development; prevention and wellness; preventive cost sharing services; amendments to establish a medication therapy management grant program, pharmacy benefit manager transparency; and allowing direct price negotiations in Medicare Part D.]

S 1796 - America's Healthy Future Act of 2009 [Sections on: health care coverage, including sections on the Health Benefits Advisory Committee, making coverage affordable, Medicaid coverage for the lowest income populations, Medicaid prescription drug coverage, changes to Medicaid payment for prescription drugs (AMP); Medicaid quality; promoting disease prevention and wellness including sections on Medicare (annual wellness visit, study on beneficiary access to immunizations, removing barriers to preventive services, and incentives for healthy lifestyles) and Medicaid (improving access to preventive services for eligible adults, incentives for healthy lifestyles, and Medicaid state plan option promoting health homes and integrated care); improving the quality and efficiency of health care including sections on physician value-based purchasing, quality infrastructure, Accountable Care Organizations, and CMS Innovation Center; strengthening primary care and other workforce improvements; Medicare Part D improvements including sections improving coverage in the Part D coverage gap, facilitation of reassignments of beneficiaries in low-income subsidy plans, strengthening formularies with respect to certain categories or classes of drugs, and limitation on removal or change of coverage of covered Part D drugs under a formulary; Medicare Advantage including section on Medicare Advantage payment; home health payment changes including section on durable medical equipment; improving Medicare for patients and providers, including sections on Medicare diabetes self-management training, and revisions to demonstration project on community health integration models in certain rural counties; administrative simplification including section on changes to HIPAA; ensuring Medicare sustainability including section on Medicare Commission; transparency and program integrity including sections on physician payment sunshine and prescription drug samples;




fraud, waste, and abuse including sections on provider screening, provider compliance and penalties; revenue items including sections on employer health insurance reporting, and annual fee on clinical laboratories; the inclusion of PBM transparency and the medications therapy management grant program in section 213 of S1679; and changes to long-term care pharmacy utilization management provisions.]

HR 3962 - Affordable Health Care for America Act [Sections on: wellness program grants; administrative simplification; ensuring adequacy of provider networks; essential benefits package defined; requiring information transparency and plan disclosure; state prohibitions on discrimination against health care providers; protection of physician prescriber information; nondiscrimination on abortion and respect for rights of conscience; study and report on methods to increase electronic health record (EHR) use by small health care providers; contracts for the offering of exchange-participating health benefits plans; payment rates for items and services; modernized payment initiatives and delivery system reforms; provider participation under the public health insurance option; limitations on health care related expenditures including distributions for medicine qualified only if for prescribed drugs or insulin; excise tax on medical devices; permitting physician assistants to order post-hospital extended care services and to provide for recognition of attending physician assistants as attending physicians to serve hospice patients; resource-based feedback program for physicians in Medicare; modifications to the physician quality reporting initiative; home infusion therapy report to Congress; durable medical equipment (DME) program improvements; MedPAC study and report on bone mass measurement; payment for biosimilar biological products; study and report on DME competitive bidding process; reducing potentially preventable hospital readmissions; post-acute care services payment reform plan and bundling pilot program; Institute of Medicine study on geographic variation in health care spending and promoting high-value health care; implementation, and Congressional review, of proposal to revise Medicare payments to promote high-value health care; phase-in of payment based on fee-for-service costs; quality bonus payments for Medicare Advantage plans; improvements to Medicare Part D including elimination of coverage gap; discounts for certain Part D drugs in original coverage gap; repeal of provision relating to submission of claims by pharmacies located in or contracting with long-term care facilities; including costs incurred by AIDS drug assistance programs and Indian Health Service in providing prescription drugs toward the annual out-of-pocket threshold under Part D; no mid-year formulary changes permitted; negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries; accurate dispensing in long-term care facilities and free generic fill; elimination of part D cost-sharing for certain non-institutionalized full-benefit dual-eligible individuals; intelligent assignment in enrollment; demonstration to promote access for Medicare beneficiaries with limited English proficiency by providing reimbursement for culturally and linguistically appropriate services; accountable care organization pilot program; medical home pilot program; coverage and waiver of cost-sharing for preventive services; expanding access to vaccines; expansion of Medicare-covered preventive services at Federally Qualified Health Centers; independence at home demonstration program; recognition of certified Diabetes Educators as certified providers for purposes of Medicare Diabetes outpatients self-management training services; comparative effectiveness research; establishment of national priorities for quality improvement; development of new quality measures; GAO evaluation of data collection process for quality measurements; multi-stakeholder pre-rulemaking input into selection of quality measures; application of quality measures; reports on financial relationships between manufacturers and distributors of covered drugs, devices, biologicals, or medical supplies under Medicare, Medicaid, or CHIP and physicians and other health care entities and between physicians and other health care entities; requirement for public reporting by hospitals and ambulatory surgical centers on health care-associated infections; pharmacy benefit managers transparency requirements; increased funding and flexibility to fight fraud and abuse; enhanced penalties for false statements on provider or supplier enrollment applications; enhanced penalties for submission of false statements material to a false claim; enhanced penalties for delaying inspections; enhanced hospice program safeguards; enhanced penalties for individuals excluded from program participation; enhanced penalties for obstruction of program audits; exclusion of certain individuals and entities from participation in Medicare and State health care programs; enhanced CMS program protection authority; enhanced Medicare, Medicaid and CHIP program disclosure requirements relating to previous affiliations; require providers and suppliers to adopt programs to reduce waste, fraud and abuse; maximum period for submission of Medicare claims reduced to not more than 12 months; telehealth expansion and enhancements;
physicians who order DME or home health services required to be Medicare enrolled physicians or eligible professionals; face-to-face encounter with patient required before eligibility certifications for home health services or DME; required repayments of Medicare and Medicaid overpayments; expanded application of hardship waivers for OIG exclusions to beneficiaries of any federal health care program; requiring provider and supplier payments under Medicare to be made through direct deposit or electronic funds transfer at insured depository institutions; under Medicaid and CHIP, required coverage of preventive services, tobacco cessation, medical home pilot program, inclusion of public health clinics under the vaccines for children program, accountable care organization pilot program, state option to disregard certain income in providing continued Medicaid coverage for certain individuals with extremely high prescription, payments to pharmacists (AMP), assuring adequate payment levels for services; report on Medicaid payments, health care acquired conditions, require providers and suppliers to adopt programs to reduce waste, fraud and abuse, overpayments, termination of provider participation under Medicaid and CHIP if terminated under Medicare or other State plan or Child health plan, Medicaid and CHIP exclusion from participation relating to certain ownership, control and management affiliations; requirement to report expanded set of data elements under Medicaid Management Information System to detect fraud and abuse, and extension of QI program; improved coordination and protection for dual-eligibles; assessment of Medicare cost-intensive diseases and conditions; establishment of Center for Medicare and Medicaid Innovation within CMS; frontline health providers loan repayment program; health workforce evaluation and assessment; improving accountability for approved medial residency training; other health care workforce issues; prevention and wellness; implementation of best practices in the delivery of health care; assistant Secretary for health information; expanded participation in 340B Program; improvements to 340B program integrity; No Child Left Unimmunized Against Influenza: demonstration program using elementary and secondary schools as influenza vaccination centers; implementation of medication management services in treatment of chronic diseases; community-based collaborative care networks; institute of medicine conference on pain; pain research at NIH; public awareness campaign on pain management; licensure pathway for biosimilar biological products; and Indian Health Care Improvement.]

HR 3590 - Patient Protection and Affordable Care Act [Sections on: reinsurance for early retirees; non-discrimination in health care; essential health benefits requirements; financial integrity in Exchanges; MedPAC study on adequacy of Medicare payments for health care providers serving in rural areas; coverage of comprehensive tobacco cessation services for pregnant women in Medicaid; distributions for medicine qualified only if for prescribed drug or insulin; administrative simplification; payment for biosimilar biological products; approval pathway for biosimilar biological products; patient-centered outcomes research; special rules; prohibition against discrimination on assisted suicide; presentation of prescription drug benefit and risk information; provider screening and other enrollment requirements under Medicare, Medicaid, and CHIP; enhanced Medicare and Medicaid program integrity provisions; maximum period for submission of Medicare claims reduced to not more than 12 months; physicians who order items or services required to be Medicare enrolled physicians or eligible professionals; requirement for physicians to provide documentation on referrals to programs at high risk of waste and abuse; face to face encounter with patient required before physicians may certify eligibility for home health services or durable medical equipment under Medicare; enhanced penalties; adjustments to the Medicare durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) competitive acquisition program; termination of provider participation under Medicaid if terminated under Medicare or other State plan; Medicaid exclusion from participation relating to certain ownership, control, and management affiliations; health information technology enrollment standards and protocols; improvements to the physician quality reporting system; hospital readmissions reduction program; community-based care transitions program; Medicare Advantage payment; demostration project to evaluate integrated care around a hospitalization; state option to provide health homes for enrollees with chronic conditions; pediatric accountable care organization demonstration project; establishment of Center for Medicare and Medicaid Innovation within CMS; Medicare shared savings program; national pilot program on payment bundling; independence at home demonstration program; establishing community health teams to support the patient-centered medical home; Medicaid coverage for the lowest income populations; elimination of exclusion of coverage of certain drugs; providing adequate pharmacy reimbursement (AMP); exemption of certain pharmacies from DMEPOS accreditation requirements; payment adjustments for home health care; Medicare coverage gap discount program; immediate reduction in coverage Medicare Part D gap in 2010; improved information for subsidy eligible individuals reassigned to prescription drug plans and MAPD plans;



improving formulary requirements for prescription drug plans and MAPD plans with respect to certain categories or classes of drugs; elimination of cost sharing for certain dual eligible individuals; uniform exceptions and appeals process for prescription drug plans and MAPD plans; Office of the Inspector General studies and reports; including costs incurred by AIDS drug assistance programs and Indian Health Service in providing prescription drugs toward the annual out-of-pocket threshold under part D; reducing wasteful dispensing of outpatient prescription drugs in long-term care facilities under prescription drug plans and MAPD plans; medication management services in treatment of chronic disease; advancing research and treatment for pain care management; National Prevention, Health Promotion and Public Health Council; clinical and community preventive services; Medicare coverage of annual wellness visit providing a personalized prevention plan; removal of barriers to preventive services in Medicare; incentives for prevention of chronic diseases in Medicaid; community transformation grants; healthy aging, living well - evaluation of community-based prevention and wellness programs for Medicare beneficiaries; CDC and employer-based wellness programs; coverage of preventive health services; immunizations; community health insurance option; level playing field; State flexibility to establish basic health programs for low-income individuals not eligible for Medicaid; ensuring the quality of care; affordable choices of health benefit plans; national strategy to improve health care quality; interagency Working Group on Health Care Quality; quality measure development; quality measurement; data collection; public reporting; health care delivery system research; quality improvement technical assistance; demonstration program to integrate quality improvement and patient safety training into clinical education of health professionals; transparency reports and reporting of physician ownership or investment interests; prescription drug sample transparency; pharmacy benefit managers transparency requirements; national health care workforce commission; health care workforce assessment; public health workforce recruitment and retention programs; allied health workforce recruitment and retention programs; grants for State and local programs; training in family medicine, general internal medicine, general pediatrics, and physician assistantship; geriatric education and training: career awards, comprehensive geriatric education; United States Public Health Sciences Track; interdisciplinary, community-based linkages (to support the existing health care workforce); Amendments: Improvements in Medicare Part D MTM programs in Freshman Amendments; Modernize Americas health care system provide for a performance-based pharmacy reimbursement program under Medicare part D (S.A. 3119); Pharmaceutical Market Access and Drug Safety Act of 2009 (S.A. 2793) Provide for establishment and maintenance of chronic care pharmacy program (S.A. 3109).]

Public Law 111-3 - Reauthorization of Childrens Health Insurance Plans on pharmacist appointment to MEDPAC

[Regulation Identifier Number (RIN) 0991-AB54] HIPAA Administrative Simplification: Standards for Privacy of Individually Identifiable Health Information [Genetic Information Nondiscrimination Act of 2008 (GINA)]
[Regulation Identifier Number (RIN) 0991AB55] HIPAA Administrative Simplification: Enforcement
(Docket No. FDA-2009-N-0247) FDA Transparency Task Force; Request for Comments
(Docket Number FDA2009N0441) Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing
(Docket Number DEA321a) Identification of Institution-based Individual Practitioners
(Docket No. FDA2009N0294) Regulation of Tobacco Products; Request for Comments
AHRQ Proposed Collection Project: Health IT Community Tracking Study 2009
HHS Draft Healthy People 2020 Objectives

Concept - Role of Pharmacist-Provided Patient Care Services in Health Care Reform
Concept - Include Pharmacists and Pharmacies in 2009 H1N1 and seasonal flu immunization activities
Concept - National Health Service Corp

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

HR 3854 - Small Business Investment and Financing Act of 2009 Section on Health Information Technology
HR 3014 - Small Business Health Information Technology Financing Act
(Public Law 111-5) American Recovery and Reinvestment Act of 2009 sections on Health Information Technology
Under Line 17: We would like to include the Office of the National Coordinator for Health Information Technology

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization